Tenax Therapeutics, Inc.
TENXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. Valued at $290.5M, TENX is a micro-cap name in its sector. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Market Cap
$290.5M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-7.77
EPS (TTM)
$-1.41
EPS (Fwd)
$-1.41
ROE
-51.7%
ROA
-32.7%
Cash
$118.8M
Total Debt
$0
Free CF
—
52W Change
86.9%
Annual Financials
Cash vs Debt
Tenax Therapeutics, Inc. reports $118.8M in cash and $0 in total debt. Return on equity stands at -51.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
As with any equity investment, TENX carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Tenax Therapeutics, Inc. and its sector.